Ruth Ruddle

Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease

Rebecca M. Hill, Sanne Kuijper, Janet C. Lindsey et al. · Cancer Cell · 2014 · 213 citations · Full text

Medicine, Genetics, Oncology +17

Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth <i>In Vitro</i> and <i>In Vivo</i>

Jane Renshaw, Kathryn R. Taylor, Ryan T. Bishop et al. · Clinical Cancer Research · 2013 · 153 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non– <i>BRCA1/2</i> -Mutant Cancers

Timothy A. Yap, Rebecca Kristeleit, Vasiliki Michalarea et al. · Cancer Discovery · 2020 · 134 citations · Full text

Medicine, Oncology, Pharmacology +13

ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma

Diana Carvalho, Kathryn R. Taylor, Nagore G. Olaciregui et al. · Communications Biology · 2019 · 122 citations · Full text

Medicine, Oncology, Pharmacology +7

Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance

Christina Guo, Adam Sharp, Bora Gürel et al. · Nature · 2023 · 120 citations · Full text

Medicine, Oncology, Pharmacology +17